| Detected | Trial | Change |
|---|---|---|
| 2026-08-13 | NCT07260175 Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in… |
Trial sites expanded: 12 -> 15 locations |
| 2026-08-11 | NCT05504720 Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of… |
Trial completed |
| 2026-08-11 | NCT05504720 Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of… |
date change Primary completion moved earlier: 2027-10 -> 2026-07-15 |
| 2026-08-11 | NCT05504720 Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of… |
date change Completion moved earlier: 2027-12 -> 2026-08-05 |
| 2026-08-08 | NCT05713838 Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation… |
Enrollment closed, study ongoing |
| 2026-08-08 | NCT05713838 Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation… |
date change Primary completion pushed: 2025-12 -> 2027-01-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization… | Hepatocellular Carcinoma | Recruiting |
| Phase 2 | |||
| NCT06207734 | Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2… | Breast Cancer | Recruiting |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic… | Extrahepatic Cholangiocarcinoma | Recruiting |
| NCT06856837 | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in… | Metastatic Colorectal Cancer | Recruiting |
| NCT06722183 | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid… | Colorectal Cancer | Recruiting |
| NCT06981325 | Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced… | Basal Cell Carcinoma (BCC) | Recruiting |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab… | Penile Squamous Cell Carcinoma (PSCC) | Recruiting |
| NCT07387198 | Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab | Merkel Cell Carcinoma, Stage I | Recruiting |
| NCT07176312 | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive… | Gastroesophageal Adenocarcinoma | Recruiting |
| NCT07260175 | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in… | Cholangiocarcinoma | Recruiting |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune… | Gastric Cancer | Active, Not Recruiting |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary… | Intrahepatic Cholangiocarcinoma | Active, Not Recruiting |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2… | Intrahepatic Cholangiocarcinoma | Active, Not Recruiting |
| NCT06680622 | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the… | Metastatic Gastro-esophageal Adenocarcinoma | Active, Not Recruiting |
| NCT06178445 | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated… | Biliary Tract Cancer | Active, Not Recruiting |
| NCT07507968 | TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal… | Esophagogastric Adenocarcinoma | Not Yet Recruiting |
| NCT05798156 | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With… | Lymphoma, Large B-Cell, Diffuse | Active, Not Recruiting |
| NCT07542678 | Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell… | Relapsed /Refractory DLBCL | Not Yet Recruiting |
| NCT04522544 | Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | Hepatocellular Carcinoma Non-resectable | Active, Not Recruiting |
| NCT05825625 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT05713838 | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation… | Esophagus Adenocarcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06731803 | Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing… | Esophagogastric Adenocarcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT07059299 | A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of… | Esophagogastric Junction Adenocarcinoma | Recruiting |
| NCT03252938 | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | Solid Tumors | Active, Not Recruiting |
| Not specified | |||
| NCT04122872 | GISAR German Interdisciplinary Sarcoma Registry | Sarcoma | Recruiting |